// App-Quantinova.ai

7060 : A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).

Researchers

Presenter

  • William Bruce Donnellan

Principal Investigators

  • Maria Diez-Campelo

  • Michael Heuser

  • Ellen K. Ritchie

  • Jeffrey Skolnik

  • Patricia Font

  • Rami S. Komrokji

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Hannover Medical School, Hannover, Germany

  • Weill Cornell Medical College of Cornell University, New York, NY

  • TetraLogic, Malvern, PA

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Moffitt Cancer Center, Tampa, FL

Locations

  • United States

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • birinapant

Outcome

  • Unknown

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02147873

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved